The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 14, 2025

Filed:

Mar. 11, 2022
Applicant:

Translate Bio, Inc., Lexington, MA (US);

Inventors:

Shrirang Karve, Lexington, MA (US);

Frank DeRosa, Lexington, MA (US);

Michael Heartlein, Lexington, MA (US);

Zarna Patel, Lexington, MA (US);

Assignee:

TRANSLATE BIO, INC., Waltham, MA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/04 (2006.01); A61K 9/00 (2006.01); A61K 9/127 (2006.01); A61K 9/19 (2006.01); A61K 9/51 (2006.01); A61K 45/06 (2006.01); A61K 47/26 (2006.01); A61P 11/00 (2006.01); B82Y 5/00 (2011.01); C07K 14/47 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/4702 (2013.01); A61K 9/0078 (2013.01); A61K 9/1272 (2013.01); A61K 9/19 (2013.01); A61K 9/51 (2013.01); A61K 45/06 (2013.01); A61K 47/26 (2013.01); A61P 11/00 (2018.01); B82Y 5/00 (2013.01); C07K 14/4712 (2013.01); A61K 38/00 (2013.01); Y10S 977/80 (2013.01);
Abstract

The present invention provides, among other things, an improved method of treating cystic fibrosis (CF) in a human subject. The method comprises administering a composition comprising an mRNA encoding a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein at a concentration of 0.5 mg/mL or greater to a human subject via nebulization. The composition is aerosolized using a nebulizer and a nominal dose of the mRNA is administered to the human subject via the nebulizer over a period of time, typically at least 30 minutes, at a suitable nebulization rate, e.g., at least 0.2 mL/minute.


Find Patent Forward Citations

Loading…